The optimal dose of CAF regimen in adjuvant chemotherapy for breast cancer patients at stage IIB
- Resource Type
- Authors
- Fatemeh Homaei-shandiz; Pedram Yazdanbakhsh; Hamid Khaloozadeh
- Source
- Mathematical biosciences. 213(2)
- Subject
- Statistics and Probability
Oncology
medicine.medical_specialty
Cyclophosphamide
Cell Survival
medicine.medical_treatment
Breast Neoplasms
General Biochemistry, Genetics and Molecular Biology
Drug Administration Schedule
Breast cancer
Clinical Protocols
Internal medicine
Antineoplastic Combined Chemotherapy Protocols
medicine
Humans
Doxorubicin
Cell Proliferation
Chemotherapy
General Immunology and Microbiology
business.industry
Applied Mathematics
CAF Regimen
General Medicine
Models, Theoretical
medicine.disease
Surgery
Regimen
Fluorouracil
Chemotherapy, Adjuvant
Modeling and Simulation
Cancer cell
Female
General Agricultural and Biological Sciences
business
medicine.drug
- Language
- ISSN
- 0025-5564
This paper deals with the idea of balancing drug effects on tumor and normal cell populations based on a variety of criteria, which is evaluated by the oncologist for breast cancer patients at stage IIB. In this paper, the optimal controller represents the optimal drug dosage of CAF (Cyclophosphamide, Adriamycin and Fluorouracil) regimen in adjuvant chemotherapy after surgery for these patients. We determined the doses of CAF regimen by minimizing a cost function with some constraints. The cost function includes the cancer cell and the normal cell growth dynamics with prescribed weighting coefficients for each patient. The physician determines these weighting coefficients based on some individual parameters. The optimal treatment schedules are computed based on a trade-off between the cancer cell reduction and the normal cell preserving. Numerical simulations are given to illustrate the accuracy of the optimal controller.